Intermediates
Products
undefined
Treatment of mild to moderate Alzheimer's syndrome. It is th™e second drug approved by FDA for Alzheimer's diseas"e in the United States. Its treatment reaches the target dose and has low toxic and side effe±cts. It has been widely recognized by our medical community, and good tolerance is its big≠gest advantage. In October 1999, Donepezil was launched in China under the trade name "Aricept", which is th®e main chemical drug against Alzheimer's disease. At present, CFD≥A has approved a number of domestic enterprises to producαe donepezil preparations, the main dosage forms are tablets, capsules, dis≠persive tablets, oral disintegrating tablets.
隐藏域元素占位
undefined
It is a nucleotide analogue developed by Bioenvision and manufactured by Genzyme. On December 29, 2004, it was approved by FDA for th☆e treatment of refractory or relapsed acute lymphoblastic leukemia (ALL) in chi♥ldren.
隐藏域元素占位
undefined
The non-steroidal anti-inflammatory drug ketoprofen is one of the most important product₹s for the treatment of arthritis. It is well tolerated and has a low •incidence of side effects
隐藏域元素占位
undefined
Pranlukast, developed by Ono, is one of the three major leukotriene receptor anta✘gonists. In clinical application, it has good therapeutic effect on atopic asthma a§nd other types of bronchial asthma, and the market prospect is huπge. In the major category of asthma drugs, leukotriene receptor antagon∞ists have the fastest growing market share.
隐藏域元素占位
undefined
Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-ori®ented and realizes industrial development through R&D innovation and technology∑ transformation.
隐藏域元素占位
undefined
undefined
Chenglian Pharmaceutical is an innovative high-tech p×harmaceutical enterprise that is market-oriented and realizes indu<strial development through R&D innovation and technol♥ogy transformation.
隐藏域元素占位
undefined
1-O-Acetyl-2,3,5-Tri-O-Benzoyl-β-D-Ribofuranose
Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that↑ is market-oriented and realizes industrial developme≠nt through R&D innovation and technology transformation.
隐藏域元素占位
undefined
English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eliqui s, Bristol-Myers Squibb/Pfizer), a direct oral factor Xa inhibitor, was approved for use in the 2↕7 EU member states. The world's first drug approved to prevent venous thromboembolism (V↔TE) in adult patients undergoing elective hip or knee replacement. From June 2019 to σJune 2020, the annual sales of apixaban products overseas reached about $15.4 billioλn, with a year-on-year growth of nearly 32%, and the API consumption reached about 23, 960 kg, with a year-on-year growth of about 28%. Compared with its main competitor, Rivaroxabπan, the drug's annual overseas sales are about $4.5σ billion higher.
隐藏域元素占位
undefined
Sitagliptin Phosphate Monohydrate
Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inhibitor de↔veloped by Merck. In October 2006, Sitagliptin phosphate Januvia was approve←d by FDA as the first DPP4 inhibitor for the treatment of tyβpe ⅱ diabetes mellitus. The characteristics of this drug are that it can> stimulate insulin secretion while reducing hunger without causing weight &gain. Hypoglycemia and edema will not occur, and it iεs suitable for diabetic patients with poor blood glucose control and freλquent hypoglycemia.
隐藏域元素占位
News
undefined
Follow WeChat
Anhui Union Pharmaceuticals Technology Co., Ltd.
Service line:
+86-21-54285906
E-mail：2880705932@qq.com
Add：4th Floor, Building B3, Creative Industry Park, He€fei, Anhui P. R. China.
Copyright © 2022 Anhui Union Pharmaceuticals Technology Co., Ltd.